Placebo-Controlled, Randomized, Double-Blind, Multicenter Study, to Demonstrate the Efficacy of 12 Weeks of Treatment With USL-221 [estradiol] on Moderate to Severe Vasomotor Symptoms and Vulvar/Vaginal Atrophy in Postmenopausal Patients.

Trial Profile

Placebo-Controlled, Randomized, Double-Blind, Multicenter Study, to Demonstrate the Efficacy of 12 Weeks of Treatment With USL-221 [estradiol] on Moderate to Severe Vasomotor Symptoms and Vulvar/Vaginal Atrophy in Postmenopausal Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Oct 2009

At a glance

  • Drugs Estradiol (Primary)
  • Indications Hot flashes; Menopausal syndrome
  • Focus Therapeutic Use
  • Sponsors Upsher-Smith
  • Most Recent Events

    • 30 Jun 2009 Results of a secondary analysis presented at the 57th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists (ACOG) according to an Upsher-Smith media release.
    • 17 Feb 2009 Results published in Menopause: Journal of the North American Menopause Society, according to a Upsher-Smith media release.
    • 25 Sep 2008 Results of additional analyses were presented at the North American Menopause Society's 19th Annual Meeting. These analyses investigated the effects of uterine status, age and body mass index on response to treatment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top